|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/519 | (2006.01) |
| A61P 37/00 | (2006.01) | ||
| A61K 45/06 | (2006.01) |
| (11) | Number of the document | 3413894 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17704548.1 |
| Date of filing the European patent application | 2017-02-10 | |
| (97) | Date of publication of the European application | 2018-12-19 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-11 |
| (46) | Date of publication of the claims translation | 2020-07-10 |
| (86) | Number | PCT/IB2017/050743 |
| Date | 2017-02-10 |
| (87) | Number | WO 2017/118965 |
| Date | 2017-07-13 |
| (30) | Number | Date | Country code |
| 16155123 | 2016-02-10 | EP | |
| 16186188 | 2016-08-29 | EP |
| (72) |
BIETH, Bruno, CH
BURKHART, Christoph, CH
CHRIST, Andreas, CH
DE BUCK, Stefan, CH
KALIS, Christoph, CH
LINDGREN, Sam, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | P13K aktyvumo arba funkcijos inhibitorių panaudojimas pirminio Sjögren'o sindromo gydymui |
| USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJÖGREN`S SYNDROME |
| Payment date | Validity (years) | Amount | |
| 2025-01-28 | 9 | 208.00 EUR |
| 2026-02-10 |